Abstracts tagged "Disease Activity"

Abstract Number: 2970 • 2017 ACR/ARHP Annual Meeting
Inhibition of Radiographic Progression in Psoriatic Arthritis By Adalimumab Independent of the Control of Clinical Disease Activity
Robert B.M. Landewé¹, Christopher T. Ritchlin², Laura C Coates³, Daniel Aletaha⁴, Benoît Guérette⁵, Ying Zhang⁵, Fabiana Ganz⁶ and Maja Hojnik⁷, ¹University of Amsterdam, Amsterdam, Netherlands, ²Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ³University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie AG, Baar, Switzerland, ⁷AbbVie, Ljubljana, Slovenia
Background/Purpose : Patients (pts) with psoriatic arthritis (PsA) may experience structural damage and irreversible functional impairment if not treated appropriately. Treatment with TNF inhibitors in…
Abstract Number: 427 • 2017 ACR/ARHP Annual Meeting
Do We Treat Men and Women Differently, and Is This a Good Thing?
Sytske Anne Bergstra¹, Cornelia F Allaart¹, Sofia Ramiro², Arvind Chopra³, Candida A. Silva⁴, Nimmisha Govind⁵ and Robert B.M. Landewé^6,7, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Center for Rheumatic Diseases, Pune, India, Pune, India, ⁴Instituto Português de Reumatologia, Lisbon, Portugal, Lisbon, Portugal, ⁵Department of Rheumatology, University of the Witwatersrand, Johannesburg, South-Africa, Johannesburg, South Africa, ⁶Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, ⁷Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands
Background/Purpose: Men seem to respond better to antirheumatic treatment than women with RA. In daily practice, expectations towards responsiveness may influence rheumatologists when making treatment…
Abstract Number: 844 • 2017 ACR/ARHP Annual Meeting
Social Support, Stress and Health Outcomes in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Charmayne M. Dunlop-Thomas, S. Sam Lim, Gaobin Bao and Cristina Drenkard, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Stress can influence immune and neuroendocrine processes, and may lead to poor outcomes in people with systemic lupus erythematosus (SLE). Social support can potentially…
Abstract Number: 1342 • 2017 ACR/ARHP Annual Meeting
Comprehensive Provider Judgment Outweighs Disease Activity Measures in the Decision to Not Escalate Therapy in Patients with Moderate to Severe Rheumatoid Arthritis
Jacob R. Stever¹, Brian Sauer², Chia-Chen Teng, MS¹, Neil Accortt³, David Collier⁴ and Grant Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., Thousand Oaks, CA
Title: Comprehensive provider judgment outweighs disease activity measures in the decision to not escalate therapy in patients with moderate to severe rheumatoid arthritis. Authors: Stever,…
Abstract Number: 1601 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Non-Adherence Is Associated with Higher Sledai Scores in a Predominantly Hispanic Population
Alexandra Perel-Winkler¹, Kayla Neville¹, James Miceli¹, Samantha Nguyen¹, Miya Okado¹, Laura Geraldino-Pardilla¹, Teja Kapoor¹, Jon T. Giles² and Anca Askanase¹, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Non-adherence to medication has been shown to impact mortality, morbidity, and health care utilization in SLE and ranges from 40-80% depending on the methods…
Abstract Number: 1917 • 2017 ACR/ARHP Annual Meeting
A Novel Type I Interferon Biomarker on B Cell Predicts with Disease Activity in SLE and Can be Measured By Cell Surface Tetherin (CD317)
Yasser M El-Sherbiny^1,2,3, Md Yuzaiful Md Yusof¹, Antonios Psarras¹, Elizabeth M.A. Hensor¹, Kumba Kabba¹, Alaa Mohamed^1,4, Miriam Wittmann⁵, Paul Emery^5,6 and Edward M Vital^1,5,7, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴Faculty of Medicine, Assiut University, Department of Rheumatology and Rehabilitation, Assiut, Egypt, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: SLE is an IFN-I-mediated disease with dysregulated handling of self-nuclear antigens triggering anti-viral immune mechanisms. The level of IFN-I activity appears to stratify for…
Abstract Number: 2434 • 2017 ACR/ARHP Annual Meeting
Baseline Expressions of Cellular microRNA-31 and microRNA-10a Predict Remission and Low Disease Activity in Patients with Early Rheumatoid Arthritis after Six and Twelve Months of Therapy
Veronika Hruskova^1,2, Klara Prajzlerova³, Martin Komarc⁴, Lucia Vernerova¹, Herman F Mann³, Maria Filkova³, Karel Pavelka³, Jiri Vencovsky³ and Ladislav Senolt³, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Anthropometrics and Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: MicroRNAs (miRNAs) post-transcriptionally regulate gene expression by targeting messenger RNAs. The expression of miRNAs was demonstrated to differ between patients with rheumatoid arthritis (RA)…
Abstract Number: 2781 • 2017 ACR/ARHP Annual Meeting
Assessing RA Disease Activity with Promis Measures Using Smartphone Technology
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Health information technology has enabled efficient measurement of PROs using Computer Adaptive Testing (CAT) methods, which have been shown to minimize missing data and…
Abstract Number: 63 • 2017 Pediatric Rheumatology Symposium
Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis
Rubén Burgos-Vargas¹, Gerd Horneff², Shirley M.L. Tse³, Pierre Quartier⁴, Kristina Unnebrink⁵ and Jaclyn K. Anderson⁶, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a category of juvenile idiopathic arthritis (JIA), with clinical features similar to those of adult spondyloarthritis (SpA). An unmet ERA…
Abstract Number: 101 • 2017 Pediatric Rheumatology Symposium
Defining Active Features of Juvenile Localized Scleroderma
Suzanne Li¹, Xiaohu Li², Elena Pope³, Katie G. Stewart⁴, Gloria Higgins⁵, C. Egla Rabinovich⁶, Kathleen O'Neil⁷, Kathleen Haines⁸, Ronald Laxer⁹, Marilynn Punaro¹⁰, Heidi Jacobe¹¹, Knut Wittkowski¹², Themba Nyirenda¹³, Ivan Foeldvari¹⁴ and Kathryn S. Torok¹⁵, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ²Mathematical Sciences, Stevens Institute of Technology, Hoboken, NJ, ³Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatrics, Nationwide Children's Hospital, Columbus, OH, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatrics, Indiana University, Indianapolis, IN, ⁸Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁹Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Texas Scottish Rite Hospital for Children, Dallas, TX, ¹¹Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Rockefeller University, New York, NY, ¹³Hackensack University Medical Center, Hackensack, NJ, ¹⁴Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹⁵Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Juvenile localized scleroderma (jLS) is the most common form of childhood scleroderma. Because of its chronicity and association with extracutaneous involvement, children are at…
Abstract Number: 5 • 2017 Pediatric Rheumatology Symposium
Effects of Puberty on Systemic Lupus Erythematosus: Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE
Kathleen O'Neil¹, Hermine Brunner², Andrew Zeft³, Anne Stevens⁴, Suzanne Li⁵, Tracey Wright⁶, Emily von Scheven⁷, B. Anne Eberhard⁸, C. Egla Rabinovich⁹ and Deborah M. Levy¹⁰, ¹Pediatrics, Indiana University, Indianapolis, IN, ²Rheumatology, PRCSG, Cincinnati, OH, ³Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ⁴University of Washington, Department of Pediatrics, Seattle, WA, ⁵Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁶Pediatrics/Rheumatology, University of TX Southwestern, Dallas, TX, ⁷Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ⁸Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁹Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Lupus often presents during puberty, and when it affects pre-pubertal children, disease activity is thought to increase at puberty. Sex hormones play some role…
Abstract Number: 175 • 2016 ACR/ARHP Annual Meeting
Suppressor of Cytokine Function One (SOCS1) Is Elevated in Non-Classical Monocytes and Correlates with Disease Activity in Systemic Lupus Erythematosus Patients
Talha Khawar¹, Jessica Cooke², Nasim Daoud³, Vaneet Sandhu⁴, Willie Davis², Warren Peters⁵, Karina Marianne D. Torralba⁶, Michelle T. Ngo⁶, Sheila Lezcano¹, Kimberly J. Payne^7,8 and Abby Jones Weldon⁹, ¹Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ²Department of Pharmaceutical and Administrative Sciences, School of Pharmacy, Loma Linda University, Loma Linda, CA, ³Division of Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ⁴Division of Rheumatology, Loma Linda University, Loma Linda, CA, ⁵Department of Preventative Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, ⁶Rheumatology, Loma Linda University, Loma Linda, CA, ⁷Center of Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁸Pathology and Human Anatomy, Loma Linda University, Loma Linda, CA, ⁹Loma Linda University, Loma Linda, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease resulting from dysregulated innate and adaptive immune components that result in an inflammatory response. Cytokines produced…
Abstract Number: 540 • 2016 ACR/ARHP Annual Meeting
The Importance of Outcome Measures in Rheumatoid Arthritis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Setting
Sergio Schwartzman¹, Keith Knapp^2,3, Gary Craig^2,3, Karen Ferguson^2,3 and Discus Analytics, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest PLLC., Spokane, WA, ³Discus Analytics LLC., Spokane, WA
The Importance of Outcome Measures in Rheumatoid Arthritis - Validity of the RAPID3 (Routine Assessment of Patient Index Data 3) in a United States “Real…
Abstract Number: 797 • 2016 ACR/ARHP Annual Meeting
Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations
Niti Goel^1,2, Brandon Barrett³, Ann Duncan⁴, Margaret-Beth Gallagher¹ and Marsha Mackey³, ¹Quintiles, Inc., Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Quintiles, Inc., Rockville, MD, ⁴Quintiles, Inc., Reading, Berkshire, United Kingdom
Background/Purpose: Background/Purpose: Randomized controlled trials (RCTs) in SLE identify specific populations of interest for eligibility, but still vary in the recruited populations. These differences may…
Abstract Number: 1370 • 2016 ACR/ARHP Annual Meeting
Development and Validation of a Composite Disease Activity Score for Juvenile Dermatomyositis
Silvia Rosina¹, Alessandro Consolaro¹, Pieter van Dijkhuizen¹, Kiran Nistala², Nicola Ruperto¹, Clarissa Pilkington³ and Angelo Ravelli¹, ¹Rheumatology, Giannina Gaslini Institute, Genova, Italy, ²Centre for Rheumatology, University College London, London, United Kingdom, ³Paediatric Rheumatology, Great Ormond Street Hospital NHS Trust, London, United Kingdom
Background/Purpose: JDM is a multisystem vasculopathic disease that primarily affects the skin and muscles. Most tools for assessment of disease activity in JDM are lenghty,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].